Posted by Michael Wonder on 05 Mar 2018
Mylan to introduce two new cost-saving HIV combination treatments in the U.S.
2 March 2018 - Mylan will launch Symfi Lo and Cimduo at a significant discount to the price of competing products to bring cost savings to the $20 billion U.S. ARV market.
Mylan today announced that it will launch two new HIV treatments, Symfi Lo and Cimduo, which were approved in February by the U.S. FDA. Mylan anticipates introducing Symfi Lo in the coming weeks and Cimduo in the second quarter of this year. These upcoming launches will extend Mylan's global anti-retroviral (ARV) platform and help address the high cost of HIV treatment in the U.S. Total spending for HIV medications in the U.S. exceeds $20 billion annually, and HIV is a top cost driver for many health care payers, such as Medicaid.
Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) 400 mg/300 mg/300 mg tablets is a once-daily, single-tablet regimen (STR) and is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 infection in adult and paediatric patients weighing at least 35 kg. Cimduo (lamivudine and tenofovir disoproxil fumarate) 300 mg/300 mg tablets is a once-daily combination of two nucleo(t)side reverse transcriptase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and paediatric patients weighing at least 35 kg.
